The Covid-19 candidate vaccine developed by the German-American alliance BioNTech and Pfizer, which has already been the subject of fruitful preliminary discussions at the European level, is showing promising results. These companies announced this on Monday 9 November, based on the first set of results from their Phase III clinical trial.
According to them, the candidate vaccine would be 90% “effective” in preventing Covid-19 infections. In this clinical trial involving 43,738...